New Cardiovascular Biomarkers in Patients with Advanced Cancer – A Prospective Study Comparing MR-proADM, MR-proANP, Copeptin, High-Sensitivity Troponin T and NT-proBNP
Journal: European Journal of Heart Failure
Year: 2024

MR-proADM is an independent predictor of mortality in advanced stage, hospitalized cancer patients without significant CV disease or current infection. The optimal MR-proADM cut-point for mortality prediction was 0.94 nmol/L with hazards for mortality being approximately 2.5 times higher. There was a continuous increase in mortality risk with stepwise increase of MR-proADM concentrations. Elevated concentrations of MR-proADM were also associated with reduced performance status and mildly reduced